"It has been enormously rewarding to work shoulder to shoulder with top scientific minds in an organization so passionate about advancing medicines."
I love the Genentech commitment to rigorous scientific investigation, data-driven decisions, and learning. Soon after joining the organization as clinical pharmacologist, I was given responsibility for developing key compounds within the heme oncology portfolio. This was an outstanding opportunity to obtain in depth knowledge of hematological malignancies and to collaborate with and learn from outstanding individuals across functions including clinical pharmacology, modeling and simulation, regulatory, nonclinical, DMPK, biomarkers, CMC, biostatistics and many more. I have learned so much and has opportunity to contribute so much more during my 4 years at Genentech compared to significantly longer tenures at other companies – there is really no comparison. Importantly, Genentech both as a company and as a group of really smart and dedicated individuals, provides the talent, experience, resources, and culture to unleash my potential to advance the development of anti-cancer therapies. I’ve found great personal satisfaction advancing novel treatments for aggressive non-Hodgkin’s lymphoma, which has afflicted both my brother and nephew early in their lives. It is easy to come to work each day with a clear sense of purpose and opportunity to make a difference for patients.
Anti-Cancer Drugs 2016 27:328–341
I am responsible for applying clinical pharmacology, modeling and simulation expertise to advance therapies for hematological malignancies including DLBCL, FL, AML, and MM. My focus has been on optimizing dose and schedule for combination therapies and ensuring that the right patients receive the right dose of our medicines. I also lead a cross-functional development team for one of our late-stage molecules that includes experts in primary pharmacology/translational research, clinical pharmacology, DMPK, preclinical and translation pharmacokinetics, and toxicology. I have the additional privilege of working with an outstanding group of direct reports and peers who bring lots of energy and innovation to drive development of molecules within the heme oncology portfolio.